Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich's AtaxiaGlobeNewsWire • 02/12/24
Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health SolutionsBusiness Wire • 02/09/24
Stay Ahead of the Game With Biogen Inc. (BIIB) Q4 Earnings: Wall Street's Insights on Key MetricsZacks Investment Research • 02/08/24
Biogen Inc. (BIIB) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research • 02/02/24
Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatmentsCNBC • 01/31/24
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024Accesswire • 01/30/24
Will Biogen Inc. (BIIB) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 01/29/24
These Could Be the Biggest Nasdaq-100 Winners in 2024, According to Wall StreetThe Motley Fool • 01/18/24
Biogen Inc. (BIIB) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research • 01/10/24
Biogen Inc. (BIIB) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)Seeking Alpha • 01/08/24